Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: The evidence to date

Pavel A. Levin, Jonathan E. Dowell

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as important players in the biology of this disease. Bevacizumab is a monoclonal antibody that binds VEGF and blocks its interaction with the VEGF receptor. Recent studies have shown benefit with the addition of bevacizumab to the combination of cisplatin and pemetrexed in MPM. This combination is now included in the National Comprehensive Cancer Network guidelines (with a category 2A recommendation) as a possible first-line treatment for unresectable MPM in appropriately selected patients. This review discusses the rationale behind the use of bevacizumab in MPM, as well as summarizes the pharmacology, efficacy, safety, and toxicity of bevacizumab across multiple trials. The use of small-molecule inhibitors of angiogenesis in the treatment of MPM is also discussed.

Original languageEnglish (US)
Pages (from-to)2057-2066
Number of pages10
JournalOncoTargets and Therapy
Volume10
DOIs
StatePublished - Apr 7 2017

Keywords

  • Angiogenesis
  • Monoclonal antibody
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: The evidence to date'. Together they form a unique fingerprint.

  • Cite this